SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Regeneron Pharmaceuticals
An SI Board Since May 1996
Posts SubjectMarks Bans Symbol
3561 104 0 REGN
Emcee:  Patrick Slevin Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
1385A Regeneron Drug Minimized Recurrence of Gout in Clinical Trial [NYT] By ANDREWDoc Bones-9/4/2008
1384Regeneron's drug to lower gout flares meets goal Wed Sep 3, 2008 11:22am EDTtnsaf-9/3/2008
1383Needle-Free Technology for the Treatment of AMD (?): siliconinvestor.comDewDiligence_on_SI-6/19/2008
1382Market Report -- Short Stories (REGN)June 5, 2008 9:36 AM ET Regeneron Pharms .Doc Bones-6/5/2008
1381lehman - - Jim Birchenough, M.D. and Charles J. Whitesell, 5/21/08 Ovarian Disasoftware salesperson-5/21/2008
1380regn down over 10 percent on P2 study in ovarian cancer. Wish I could read this fred hayes-5/21/2008
1379Sanofi-Aventis, Regeneron cancer drug misses goal Wednesday May 21, 8:08 am ET Doc Bones-5/21/2008
13781Q08 ex-US Lucentis sales: $195M, +15% vs 4Q07: siliconinvestor.com Off-label DewDiligence_on_SI-4/21/2008
1377Lucentis’ share of US new Rx’s slipped from 50% to the low 40’s in the most receDewDiligence_on_SI-4/10/2008
1376ARCALYST(TM) (rilonacept), First and Only FDA-approved Treatment for Cryopyrin-Atnsaf-3/25/2008
1375Few more details on VIEW2. While 300 subjects per arm does not generate large pMiljenko Zuanic-3/21/2008
1374After long +20 years: "FDA Approves Regeneron's ARCALYST(TM) (rilonaceMiljenko Zuanic-2/27/2008
1373From Sanofi PR, en.sanofi-aventis.com "Oncology The database lock for theMiljenko Zuanic-2/12/2008
1372Just posted on DYAX board. Tie-1 is now "active target". REGN is sloMiljenko Zuanic-2/12/2008
1371Dyax Corp. Enters Into Antibody Agreements with Sanofi-aventis for the Fully Humscaram(o)uche-2/12/2008
1370<i>Marry Christmas!</i> I can’t because I’m already happily marriedDewDiligence_on_SI-12/24/2007
1369Marry Christmas!Miljenko Zuanic-12/24/2007
1368clinicaltrials.gov Why not adaptive PII/III trial designee: PII (200 pts:PFS) eMiljenko Zuanic-12/18/2007
1367<<If I'm reading this correctly, they don't seem to discuss the quMiljenko Zuanic-12/15/2007
1366Thanks for your reply Miljenko. I've re-entered REGN a few years ago when iSpartex-12/14/2007
1365Interesting paper - gives them a good handle on dosing if nothing else. If I&Biomaven-12/14/2007
1364More on free and bound VEGF level, cancer and non-cancer subjects. pnas.org ThMiljenko Zuanic-12/14/2007
1363REGN forward (6 - 12 months) cash/share value ( ~$600M/+80M shares) is ~7.5-8$. Miljenko Zuanic-12/13/2007
1362Well the REGN cash position is around $12-13 bucks a share. What does a bottom Spartex-12/13/2007
1361AC split vote on sNDA: first line Avastin for MBC, generated opportunity for VEGMiljenko Zuanic-12/5/2007
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News